GoodRx (NASDAQ:GDRX) Upgraded by Wall Street Zen to “Buy” Rating

Wall Street Zen upgraded shares of GoodRx (NASDAQ:GDRX) from a hold rating to a buy rating in a report issued on Saturday.

A number of other research analysts have also issued reports on the company. Weiss Ratings reiterated a “sell (d)” rating on shares of GoodRx in a research report on Tuesday, December 23rd. TD Cowen reduced their price objective on shares of GoodRx from $7.00 to $6.00 and set a “buy” rating for the company in a research report on Monday, November 10th. UBS Group reaffirmed a “reduce” rating on shares of GoodRx in a report on Monday, January 5th. Barclays began coverage on shares of GoodRx in a research note on Monday, December 8th. They set an “underweight” rating and a $3.00 target price for the company. Finally, Morgan Stanley reduced their price target on shares of GoodRx from $5.00 to $4.00 and set an “equal weight” rating for the company in a research report on Thursday, December 18th. Five research analysts have rated the stock with a Buy rating, five have given a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $4.91.

GoodRx Price Performance

GDRX opened at $2.68 on Friday. GoodRx has a fifty-two week low of $2.61 and a fifty-two week high of $5.81. The company has a debt-to-equity ratio of 0.81, a quick ratio of 3.11 and a current ratio of 3.11. The company has a fifty day moving average of $2.79 and a two-hundred day moving average of $3.74. The stock has a market capitalization of $909.67 million, a price-to-earnings ratio of 29.78, a PEG ratio of 1.02 and a beta of 1.45.

GoodRx (NASDAQ:GDRX) last posted its earnings results on Tuesday, November 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). GoodRx had a return on equity of 9.73% and a net margin of 3.97%.The firm had revenue of $196.03 million for the quarter, compared to analysts’ expectations of $195.17 million. During the same period in the previous year, the company earned $0.08 earnings per share. The company’s revenue was up .4% compared to the same quarter last year. On average, research analysts expect that GoodRx will post 0.13 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in GDRX. Quarry LP acquired a new stake in shares of GoodRx in the third quarter valued at approximately $33,000. Boothbay Fund Management LLC purchased a new stake in GoodRx in the 3rd quarter valued at $43,000. Shay Capital LLC acquired a new stake in shares of GoodRx in the 3rd quarter worth $47,000. Cetera Investment Advisers purchased a new position in shares of GoodRx during the 2nd quarter worth $50,000. Finally, Walled Lake Planning & Wealth Management LLC purchased a new position in shares of GoodRx during the 2nd quarter worth $55,000. 63.77% of the stock is currently owned by institutional investors and hedge funds.

GoodRx Company Profile

GoodRx Holdings, Inc (NASDAQ: GDRX) operates a digital healthcare platform designed to help consumers compare prescription drug prices at retail pharmacies across the United States. Through its website and mobile applications, GoodRx aggregates pricing and discount information from a wide network of pharmacies, enabling users to access coupons and savings programs on both generic and brand-name medications. The platform also features price transparency tools that inform patients about cost variations and available discounts to alleviate the financial burden of prescription medications.

In addition to its core drug pricing service, GoodRx offers telehealth services under the GoodRx Care brand, providing virtual consultations for a range of non-emergency conditions and prescription needs.